BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Regulation of CYP26A1 expression by selective RAR and RXR agonists in human NB4 promyelocytic leukemia cells.

All-trans retinoic acid (ATRA) can induce complete remission in acute promyelocytic leukemia (APL), but resistance to this treatment develops rapidly partly due to increased ATRA metabolism.

Among the cytochrome P450s (CYPs) involved in ATRA metabolism, the ATRA-inducible cytochrome P450 26A1 (CYP26A1) is particularly active although the molecular mechanisms involved in its regulation are not well defined in the target leukemia cells.

To study CYP26A1 expression and regulation in APL cells, we used the NB4 promyelocytic leukemia cell line.

To further define CYP26A1 induction mechanisms in the NB4 leukemia cells, we used RARs and RXR selective agonists.

In conclusion, we have shown that CYP26A1 induction is not essential for the granulocytic maturation of NB4 leukemia cells, and that CYP26A1 induction requires the activation of both RARalpha and RXR in these cells.

[MeSH-major] Cytochrome P-450 Enzyme System / biosynthesis. Leukemia, Promyelocytic, Acute / enzymology. Receptors, Retinoic Acid / agonists. Retinoid X Receptors / agonists

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15896339.001).

[ISSN] 0006-2952

[Journal-full-title] Biochemical pharmacology

[ISO-abbreviation] Biochem. Pharmacol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Receptors, Retinoic Acid; 0 / Retinoid X Receptors; 0 / retinoic acid receptor alpha; 0 / retinoic acid receptor beta; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / retinoic acid 4-hydroxylase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Clinical observation and follow-up study on acute promyelocytic leukemia in childhood treated mainly with arsenic trioxide].

[MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use

[MeSH-minor] Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Remission Induction / methods. Survival Rate. Treatment Outcome

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16083560.001).

[ISSN] 0578-1310

[Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics

[ISO-abbreviation] Zhonghua Er Ke Za Zhi

[Language] chi

[Publication-type] Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Is cytarabine required in the treatment of acute promyelocytic leukemia?

Until the late 1980s, chemotherapy with anthracyclines and cytarabine (AraC) was the only treatment approach for acute promyelocytic leukemia (APL), as for other types of acute myeloid leukemia.

Several groups have reported high rates of complete remission and low rates of relapse with ATRA and chemotherapy using anthracyclines alone, suggesting that AraC could be avoided in the chemotherapy of APL, reducing toxicity.

[MeSH-major] Cytarabine / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Adult. Anthracyclines / administration & dosage. Anthracyclines / adverse effects. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Humans. Middle Aged. Multicenter Studies as Topic. Randomized Controlled Trials as Topic. Remission Induction. Treatment Outcome. Tretinoin / administration & dosage. Tretinoin / adverse effects

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 1995 Sep 1;86(5):1717-28 [7655004.001]

[Cites] Leukemia. 1992;6 Suppl 1:64-6 [1548938.001]

[Cites] Cancer. 1997 Dec 1;80(11 Suppl):2181-5 [9395031.001]

[Cites] Semin Hematol. 1996 Oct;33(4 Suppl 3):12-7 [8916311.001]

[Cites] Blood. 1993 Dec 1;82(11):3241-9 [8241496.001]

[Cites] Blood. 1992 Feb 1;79(3):543-53 [1732003.001]

[Cites] Leuk Lymphoma. 1991;4(4):239-48 [27463043.001]

[Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]

[Cites] Cell. 1991 Aug 23;66(4):675-84 [1652369.001]

[Cites] N Engl J Med. 1991 May 16;324(20):1385-93 [1850498.001]

[Cites] Blood. 2004 Feb 15;103(4):1237-43 [14576047.001]

[Cites] Blood. 1998 Oct 15;92(8):2712-8 [9763554.001]

[Cites] Blood. 1989 Apr;73(5):1116-22 [2930837.001]

[Cites] Blood. 2010 Oct 28;116(17):3171-9 [20644121.001]

[Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]

[Cites] Leukemia. 1994;8 Suppl 2:S38-41 [7815835.001]

[Cites] Blood. 1999 Aug 15;94(4):1192-200 [10438706.001]

[Cites] Am J Med. 1984 May;76(5):827-41 [6586073.001]

[Cites] Leukemia. 2005 Feb;19(2):230-3 [15565164.001]

[Cites] J Clin Oncol. 1997 Feb;15(2):483-90 [9053469.001]

[Cites] Blood. 2002 Nov 1;100(9):3141-6 [12384411.001]

[Cites] Nouv Rev Fr Hematol. 1984;26(6):371-8 [6597407.001]

[Cites] Ann Intern Med. 1992 Aug 15;117(4):292-6 [1637024.001]

[Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]

[Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]

(PMID = 20425342.001).

[ISSN] 1558-822X

[Journal-full-title] Current hematologic malignancy reports

[ISO-abbreviation] Curr Hematol Malig Rep

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Anthracyclines; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin

[Number-of-references] 26

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Auto-SCT for AML in second remission: CALGB study 9620.

We studied the feasibility and efficacy of a two-step approach to Auto-SCT for patients with AML in second remission.

The most important prognostic factor was cytogenetics, with acute promyelocytic leukemia (APL) patients having a 5-year DFS of 67% compared with 16% for others.

[MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Cytarabine / therapeutic use. Etoposide / therapeutic use. Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation

[MeSH-minor] Adult. Aged. Aging. Antigens, CD34 / analysis. Combined Modality Therapy / adverse effects. Disease-Free Survival. Female. Humans. Ideal Body Weight. Infusions, Intravenous. Kaplan-Meier Estimate. Male. Middle Aged. Remission Induction. Transplantation, Autologous. Treatment Outcome. Treatment Refusal. Young Adult

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. ETOPOSIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19289999.001).

[ISSN] 1476-5365

[Journal-full-title] Bone marrow transplantation

[ISO-abbreviation] Bone Marrow Transplant.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04457; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA21060; United States / NCI NIH HHS / CA / CA26806; United States / NCI NIH HHS / CA / CA29165; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA60138; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA77658

[Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, CD34; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.

All-trans retinoic acid (ATRA)/arsenic trioxide (ATO) combination-based therapy has benefitted newly diagnosed acute promyelocytic leukemia (APL) in short-term studies, but the long-term efficacy and safety remained unclear.

Eighty patients (94.1%) entered complete remission (CR).

[MeSH-major] Arsenicals / adverse effects. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / diagnosis. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / adverse effects. Oxides / therapeutic use. Tretinoin / adverse effects. Tretinoin / therapeutic use

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2008 Mar 1;111(5):2527-37 [17965322.001]

[Cites] Leuk Res. 2007 Nov;31(11):1585-7 [17416415.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4826-31 [18344322.001]

[Cites] Nat Cell Biol. 2008 May;10(5):547-55 [18408733.001]

[Cites] Pediatr Blood Cancer. 2008 Jul;51(1):133-5 [18293388.001]

[Cites] Blood. 2008 Nov 1;112(9):3587-90 [18703707.001]

[Cites] Blood. 2007 Jan 15;109(2):740-6 [16968895.001]

[Cites] Leukemia. 2000 Aug;14(8):1371-7 [10942231.001]

[Cites] Blood. 2001 Jan 1;97(1):264-9 [11133770.001]

[Cites] Br J Haematol. 2002 Apr;117(1):130-2 [11918543.001]

[Cites] Hematol J. 2001;2(5):330-40 [11920269.001]

[Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]

[Cites] Eur J Haematol. 2002 May;68(5):310-3 [12144538.001]

[Cites] Blood. 2002 Dec 15;100(13):4298-302 [12393590.001]

[Cites] J Clin Oncol. 2003 Jun 15;21(12):2326-34 [12805334.001]

[Cites] Leukemia. 2003 Sep;17(9):1916-7; author reply 1918 [12970801.001]

[Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]

[Cites] Ai Zheng. 2004 Apr;23(4):430-4 [15087033.001]

[Cites] Hematol Oncol. 2004 Jun;22(2):63-71 [15468344.001]

[Cites] Blood. 1973 Apr;41(4):489-96 [4510926.001]

[Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]

[Cites] Blood. 1993 Dec 1;82(11):3241-9 [8241496.001]

[Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]

[Cites] Blood. 1996 Oct 15;88(8):2826-32 [8874178.001]

[Cites] Leukemia. 1996 Dec;10(12):1911-8 [8946930.001]

[Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]

[Cites] Sci Total Environ. 1997 Sep 26;204(2):147-60 [9301099.001]

[Cites] Leukemia. 1997 Sep;11(9):1447-52 [9305596.001]

[Cites] Blood. 1998 Jun 1;91(11):4300-10 [9596679.001]

[Cites] J Exp Med. 1999 Apr 5;189(7):1043-52 [10190895.001]

[Cites] Blood. 1999 May 15;93(10):3167-215 [10233871.001]

[Cites] Bone Marrow Transplant. 1999 Aug;24(3):345-8 [10455379.001]

[Cites] Acta Med Scand. 1957 Nov 29;159(3):189-94 [13508085.001]

[Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8 [15894607.001]

[Cites] Blood. 2005 Nov 15;106(10):3658-65 [16076872.001]

[Cites] Ann Oncol. 2006 Jan;17(1):131-4 [16227315.001]

[Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]

[Cites] Blood. 2006 May 1;107(9):3469-73 [16373661.001]

[Cites] Leukemia. 2006 Aug;20(8):1393-9 [16728984.001]

[Cites] Cancer. 2007 Apr 1;109(7):1355-9 [17326049.001]

[Cites] Blood. 2008 Mar 1;111(5):2505-15 [18299451.001]

(PMID = 19225113.001).

[ISSN] 1091-6490

[Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America

[ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / AQP9 protein, human; 0 / Aquaporins; 0 / Arsenicals; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

[Other-IDs] NLM/ PMC2651325

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Arsenic induces clinical remission in patients with acute promyelocytic leukemia and has potential for treatment of other cancers.

MedlinePlus Health Information. consumer health - Melanoma.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mol Cancer Ther. 2006 Dec;5(12):2963-9 [17172401.001]

[Cites] J Pharmacol Exp Ther. 2005 May;313(2):877-87 [15722406.001]

[Cites] Biochem Pharmacol. 2000 Jan 1;59(1):43-5 [10605933.001]

[Cites] Environ Health Perspect. 2000 May;108(5):393-7 [10811564.001]

[Cites] Biochem Pharmacol. 2000 Sep 15;60(6):771-80 [10930531.001]

[Cites] J Biol Chem. 2000 Nov 17;275(46):36062-6 [10967126.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1643-8 [11172004.001]

[Cites] J Biol Chem. 2001 Apr 6;276(14):11414-9 [11150309.001]

[Cites] Oncologist. 2001;6 Suppl 2:22-8 [11331437.001]

[Cites] Mol Pharmacol. 2001 Aug;60(2):302-9 [11455017.001]

[Cites] EMBO J. 2001 Nov 15;20(22):6371-82 [11707408.001]

[Cites] Biochem Biophys Res Commun. 2002 Mar 8;291(4):861-7 [11866444.001]

[Cites] Toxicol Appl Pharmacol. 2002 Apr 15;180(2):83-91 [11969375.001]

[Cites] Mol Cell Biochem. 2002 May-Jun;234-235(1-2):301-8 [12162448.001]

[Cites] Mol Pharmacol. 2002 Sep;62(3):529-38 [12181429.001]

[Cites] Leuk Lymphoma. 2002 Aug;43(8):1535-40 [12400595.001]

[Cites] Leukemia. 2003 May;17(5):931-40 [12750708.001]

[Cites] Oncogene. 2003 May 19;22(20):3138-51 [12789290.001]

[Cites] Leukemia. 2003 Jul;17(7):1333-7 [12835721.001]

[Cites] Carcinogenesis. 2004 Jan;25(1):21-8 [14514659.001]

[Cites] Cancer Res. 2004 Apr 1;64(7):2502-8 [15059905.001]

[Cites] J Biol Chem. 2004 May 21;279(21):22747-58 [15028728.001]

[Cites] J Biol Chem. 2004 Jul 30;279(31):32700-8 [15161912.001]

[Cites] Int J Cancer. 1977 Dec 15;20(6):869-72 [271143.001]

[Cites] Br J Cancer. 1992 Nov;66(5):888-92 [1419632.001]

[Cites] Biochem J. 1992 Dec 15;288 ( Pt 3):977-82 [1472011.001]

[Cites] Biochem Biophys Res Commun. 1995 Mar 8;208(1):345-52 [7887949.001]

[Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]

[Cites] Mutat Res. 1997 Jun;386(3):291-8 [9219566.001]

[Cites] Oncol Res. 1997;9(5):237-48 [9306431.001]

[Cites] Biochem J. 2005 Feb 15;386(Pt 1):1-13 [15521820.001]

[Cites] Oncogene. 2005 Jan 20;24(4):616-26 [15580309.001]

[Cites] Arch Toxicol. 2005 Apr;79(4):183-91 [15526190.001]

[Cites] Br J Cancer. 2005 Jul 25;93(2):216-23 [15999103.001]

[Cites] Cell Cycle. 2005 Oct;4(10):1385-8 [16138009.001]

[Cites] Toxicol Sci. 2006 Jan;89(1):164-72 [16207941.001]

[Cites] Exp Cell Res. 2006 May 1;312(8):1401-17 [16487513.001]

[Cites] J Pharmacol Exp Ther. 2006 Jul;318(1):142-51 [16614167.001]

[Cites] J Biol Chem. 2006 Nov 10;281(45):34113-23 [16973625.001]

[Cites] Curr Opin Cell Biol. 1997 Dec;9(6):807-14 [9425345.001]

[Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):124-33 [9450572.001]

[Cites] Blood. 1998 Sep 1;92(5):1497-504 [9716575.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3706-11 [10097101.001]

[Cites] J Natl Cancer Inst. 1999 May 5;91(9):772-8 [10328107.001]

[Cites] Exp Cell Res. 1999 Jun 15;249(2):413-21 [10366441.001]

[Cites] Gynecol Oncol. 2007 Apr;105(1):66-73 [17234259.001]

(PMID = 18328521.001).

[ISSN] 0041-008X

[Journal-full-title] Toxicology and applied pharmacology

[ISO-abbreviation] Toxicol. Appl. Pharmacol.

[Language] ENG

[Grant] United States / NIEHS NIH HHS / ES / P30 ES014443-01A1; United States / NIEHS NIH HHS / ES / P30 ES014443; United States / NIEHS NIH HHS / ES / ES011314-05S1; United States / NIEHS NIH HHS / ES / ES011314-05; United States / NIEHS NIH HHS / ES / P30ES014443; United States / NIEHS NIH HHS / ES / P30 ES001247; United States / PHS HHS / / R01E S011314; United States / NIEHS NIH HHS / ES / T32ES011564; United States / NIEHS NIH HHS / ES / T32 ES011564; United States / NIEHS NIH HHS / ES / T32 ES011564-03; United States / NIEHS NIH HHS / ES / P30ES001247; United States / NIEHS NIH HHS / ES / ES011564-03; United States / NIEHS NIH HHS / ES / ES013372-03; United States / NIEHS NIH HHS / ES / F30 ES013372-03; United States / NIEHS NIH HHS / ES / R01 ES011314; United States / NIEHS NIH HHS / ES / R01 ES011314-05S1; United States / NIEHS NIH HHS / ES / R01 ES011314-05

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Arsenites; 0 / Sodium Compounds; 48OVY2OC72 / sodium arsenite

[Other-IDs] NLM/ NIHMS54377; NLM/ PMC2474465

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Retinoic acid-induced CD38 antigen promotes leukemia cells attachment and interferon-gamma/interleukin-1beta-dependent apoptosis of endothelial cells: implications in the etiology of retinoic acid syndrome.

All-trans retinoic acid (RA) treatment of patients with acute promyelocytic leukemia (APL) induces complete remission in more than 90% of the cases.

Importantly, RA-induced CD38 expression promoted strong attachment of leukemia cells to endothelial cells, and incubation of endothelial cells with either high concentration (100 ng/ml) of IFN-gamma alone or low concentration of IL-1beta and IFN-gamma (10 ng/ml, each) induced strong apoptotic responses as revealed by caspase-8 activation and DNA fragmentation.

[MeSH-major] Antigens, CD38 / metabolism. Apoptosis / drug effects. Endothelium, Vascular / pathology. Interferon-gamma / pharmacology. Interleukin-1beta / pharmacology. Leukemia, Promyelocytic, Acute / pathology. Tretinoin / pharmacology

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. NITRIC OXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16920192.001).

[ISSN] 0145-2126

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA092115; United States / PHS HHS / / P01 PA 55164

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-1beta; 0 / Receptors, Retinoic Acid; 31C4KY9ESH / Nitric Oxide; 5688UTC01R / Tretinoin; 82115-62-6 / Interferon-gamma; EC 3.2.2.5 / Antigens, CD38

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.

PURPOSE: Several phase II studies have suggested that cytarabine (AraC) was not required in the treatment of newly diagnosed acute promyelocytic leukemia (APL) patients receiving all-trans-retinoic acid (ATRA), an anthracycline, and maintenance therapy, and we aimed at confirming this finding in a randomized trial.

RESULTS: Overall, 328 (96.5%) of 340 patients achieved complete remission (CR).

[MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Adult. Daunorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Remission Induction. Survival Analysis. Tretinoin / administration & dosage

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. DAUNORUBICIN .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17116939.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; ZS7284E0ZP / Daunorubicin

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome.

BACKGROUND: Even after the introduction of all-trans retinoic acid (ATRA), early hemorrhagic death remains a major cause of remission induction failure for acute promyelocytic leukemia (APL).

METHODS: To investigate severe hemorrhagic complications during remission induction therapy with respect to incidence, risk factors, and influence on outcome.

Results were analyzed for 279 patients enrolled in the APL97 study conducted by the Japan Adult Leukemia Study Group (JALSG).

Nine of them succumbed to an early death, while the remaining nine patients eventually achieved complete remission (CR).

[MeSH-major] Hemorrhage / etiology. Hemorrhage / pathology. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / pathology

[MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Remission Induction. Risk Factors. Treatment Outcome

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Bleeding.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17241371.001).

[ISSN] 0902-4441

[Journal-full-title] European journal of haematology

[ISO-abbreviation] Eur. J. Haematol.

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] Denmark

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] ASCORBIC ACID - MODULATION OF ARSENIC TRIOXIDE TOXICITY: IMPLICATION FOR THE CLINICAL TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA.

BACKGROUND: Acute Promyelocytic Leukemia (APL) is a subtype of acute leukemia which can affect people of any age.

Recent in vitro and in vivo studies have shown that arsenic trioxide (ATO) can induce clinical remission in de-novo and APL patients that have relapsed from conventional treatment.

AIM: The aim of this research was to study the modulatory effect of AA on ATO-induced oxidative stress in leukemia cells.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 26549974.001).

[ISSN] 1257-2535

[Journal-full-title] Metal ions in biology and medicine : proceedings of the ... International Symposium on Metal Ions in Biology and Medicine held ... = Les ions metalliques en biologie et en medecine : ... Symposium international sur les ions metalliques ...

[ISO-abbreviation] Met Ions Biol Med

[Language] ENG

[Grant] United States / NCRR NIH HHS / RR / G12 RR013459; United States / NCRR NIH HHS / RR / G12 RR013459-010007

[Publication-type] JOURNAL ARTICLE

[Publication-country] France

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Promyelocytic sarcoma of the spine: a case report and review of the literature.

It can be present before, concurrently with, or after the diagnosis of acute myeloid leukemia.

MS is extremely uncommon in acute promyelocytic leukemia (APL).

The patient presented with neurologic symptoms due to a paravertebral mass of MS after 7 years of complete remission.

Systemic treatment was also given with combined arsenic trioxide and all-trans retinoic acid and the patient was able to achieve a second prolonged clinical and molecular remission.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 1991 Nov 15;68(10):2281-3 [1913463.001]

[Cites] Ophthalmology. 1992 Sep;99(9):1463-7 [1407980.001]

[Cites] Haematologia (Budap). 1989;22(3):195-9 [2583600.001]

[Cites] Cancer. 1989 Jun 1;63(11):2192-200 [2785843.001]

[Cites] Cancer. 1987 Jan 1;59(1):94-8 [3466663.001]

[Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]

[Cites] Cancer. 1994 Apr 15;73(8):2107-12 [7512442.001]

[Cites] Leuk Lymphoma. 1994 Aug;14(5-6):453-6 [7812204.001]

[Cites] Cancer. 1994 Oct 1;74(7):1882-6 [8082094.001]

[Cites] Am J Clin Pathol. 1993 Sep;100(3):276-84 [8379536.001]

[Cites] Leuk Lymphoma. 1996 Jun;22(1-2):183-6 [8724548.001]

[Cites] Semin Oncol. 1997 Feb;24(1):92-102 [9045308.001]

[Cites] Intern Med. 1997 Jul;36(7):484-6 [9240497.001]

[Cites] Br J Haematol. 1997 Aug;98(2):437-9 [9266945.001]

[Cites] Bone Marrow Transplant. 1997 Oct;20(8):689-90 [9383233.001]

[Cites] Cancer. 1998 Oct 15;83(8):1522-8 [9781945.001]

[Cites] Leuk Lymphoma. 1999 Apr;33(3-4):219-29 [10221502.001]

[Cites] Histopathology. 1999 May;34(5):391-8 [10231412.001]

[Cites] Haematologica. 1999 Jun;84(6):565-6 [10366808.001]

[Cites] Leukemia. 1999 Sep;13(9):1406-8 [10482992.001]

[Cites] Leukemia. 2000 Jun;14(6):1006-13 [10865965.001]

[Cites] Haematologica. 2000 Jul;85(7):758-62 [10897129.001]

[Cites] Eur J Haematol. 2000 Mar;64(3):201-3 [10997887.001]

[Cites] J Clin Oncol. 2000 Oct 1;18(19):3435-7 [11013284.001]

[Cites] J Clin Oncol. 2001 Oct 15;19(20):4023-8 [11600603.001]

[Cites] Cancer. 2002 Mar 15;94(6):1739-46 [11920536.001]

[Cites] Haematologica. 2002 May;87(5):485-9 [12010661.001]

[Cites] Leukemia. 2002 Jun;16(6):1127-30 [12040443.001]

[Cites] Eur J Haematol. 2002 May;68(5):310-3 [12144538.001]

[Cites] Ann Pharmacother. 2002 Dec;36(12):1900-6 [12452754.001]

[Cites] Leuk Lymphoma. 2003 Jan;44(1):189-91 [12691162.001]

[Cites] Ann Oncol. 2003 May;14(5):752-7 [12702530.001]

[Cites] Leukemia. 2003 Jun;17(6):1100-3 [12764375.001]

[Cites] Leukemia. 2003 Jul;17(7):1418-9 [12835735.001]

[Cites] Leukemia. 2003 Aug;17(8):1454-63 [12886231.001]

[Cites] Best Pract Res Clin Haematol. 2003 Sep;16(3):453-61 [12935962.001]

[Cites] Best Pract Res Clin Haematol. 2003 Sep;16(3):521-34 [12935967.001]

[Cites] J Korean Med Sci. 2004 Apr;19(2):311-4 [15082912.001]

[Cites] Leuk Res. 2004 Sep;28(9):991-4 [15234578.001]

[Cites] Acta Med Okayama. 2004 Oct;58(5):251-4 [15666994.001]

[Cites] Leukemia. 2005 Mar;19(3):479-80 [15674358.001]

[Cites] Int J Hematol. 2005 Oct;82(3):224-9 [16207595.001]

[Cites] Leukemia. 2006 Jan;20(1):35-41 [16307026.001]

[Cites] Blood. 2006 May 1;107(9):3469-73 [16373661.001]

[Cites] Ann Hematol. 2006 Oct;85(10):741-2 [16718497.001]

[Cites] Int J Hematol. 2006 May;83(4):337-40 [16757435.001]

[Cites] Acta Haematol. 2007;117(2):106-8 [17135723.001]

[Cites] Leukemia. 2007 Mar;21(3):446-52 [17205057.001]

[Cites] J Neurosurg. 2006 Dec;105(6):912-5 [17405265.001]

[Cites] Pediatr Blood Cancer. 2008 Mar;50(3):657-60 [17437290.001]

[Cites] Ann Transplant. 2007;12(3):33-8 [18290568.001]

[Cites] Blood. 2009 Feb 26;113(9):1875-91 [18812465.001]

[Cites] J BUON. 2008 Oct-Dec;13(4):589-92 [19145688.001]

[Cites] Clin Lab Haematol. 1990;12(1):97-9 [2344722.001]

(PMID = 20339529.001).

[ISSN] 1687-9112

[Journal-full-title] Advances in hematology

[ISO-abbreviation] Adv Hematol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Egypt

[Other-IDs] NLM/ PMC2843861

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].

BACKGROUND: The studies have demonstrated that arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) takes effects in treatment of acute promyelocytic leukemia (APL) through different underlying mechanisms.

DATA EXTRACTION AND ANALYSIS: Related data concerning complete remission rate, overall survival rate, and disease free survival rate, time to complete remission, relapse rate, mortality and adverse reactions were extracted independently by two reviewers.

Compared with ATO monotherapy, ATO plus ATRA could improve time to complete remission and relapse rate of newly diagnosed APL, but could not improve the complete remission rate, disease free survival rate, mortality and liver dysfunction of relapsed APL patients based on meta-analysis and sensitivity analysis.

Compared with ATRA monotherapy, ATO plus ATRA shortened the time to complete remission, improved the disease free survival rate and relapse rate, but increased the incidence of edema during the treatment.

Compared with chemotherapy with ATO plus ATRA, ATO plus ATRA could improve the complete remission rate, relapse rate, mortality and adverse reactions.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use. Tretinoin / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19912733.001).

[ISSN] 1672-1977

[Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine

[ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao

[Language] chi

[Publication-type] English Abstract; Journal Article; Meta-Analysis; Review

[Publication-country] China

[Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Co-expression of promyelocytic leukemia protein abrogated the repressive effect of Daxx on C/EBPbeta as well as the direct interaction of Daxx and C/EBPbeta, presumably by re-recruiting Daxx to PML-oncogenic domains.

In acute promyelocytic leukemia (APL) cells, C/EBPbeta activity is known to be required for all-trans-retinoic acid-induced cell differentiation and disease remission.

Overall, our data identify Daxx as a new negative regulator of C/EBPbeta and provide first clues for a link between abrogation of Daxx-C/EBPbeta complex formation and APL remission.

[MeSH-minor] Adaptor Proteins, Signal Transducing. Animals. Cell Differentiation. Fibroblasts / metabolism. Gene Expression Regulation. HeLa Cells. Humans. Leukemia, Promyelocytic, Acute / metabolism. Nuclear Proteins. Phosphorylation. Protein Structure, Tertiary. Quail. Tretinoin / metabolism. p300-CBP Transcription Factors / metabolism

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mol Cell Biol. 2004 Dec;24(24):10529-41 [15572661.001]

[Cites] J Biol Chem. 2004 Nov 12;279(46):48013-23 [15339933.001]

[Cites] Cancer Cell. 2005 Feb;7(2):143-53 [15710327.001]

[Cites] J Immunol. 2006 Apr 15;176(8):4843-51 [16585579.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):16973-8 [16287980.001]

[Cites] J Biol Chem. 2005 Mar 18;280(11):10164-73 [15637079.001]

[Cites] EMBO J. 2006 Sep 6;25(17):3955-65 [16917507.001]

[Cites] Mol Cell. 2006 Nov 3;24(3):341-54 [17081986.001]

[Cites] J Biol Chem. 2007 Jan 12;282(2):956-67 [17110376.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2703-8 [17301242.001]

[Cites] J Mol Biol. 2007 Apr 27;368(2):388-97 [17362989.001]

[Cites] Biochem Soc Trans. 2007 Dec;35(Pt 6):1397-400 [18031230.001]

[Cites] Mol Cell Biol. 2008 Mar;28(6):2102-12 [18195047.001]

[Cites] Oncogene. 2008 Apr 3;27(15):2177-86 [17952115.001]

[Cites] Curr Opin Cell Biol. 2008 Apr;20(2):180-5 [18358708.001]

[Cites] Genes Dev. 2008 Apr 15;22(8):998-1010 [18413714.001]

[Cites] Nat Cell Biol. 2008 May;10(5):547-55 [18408733.001]

[Cites] Nat Cell Biol. 2008 May;10(5):538-46 [18408734.001]

[Cites] Mol Cell Endocrinol. 2008 Jul 16;289(1-2):94-101 [18486321.001]

[Cites] J Biol Chem. 2008 Sep 26;283(39):26357-63 [18647749.001]

[Cites] Mol Cell Biol. 2000 Mar;20(5):1784-96 [10669754.001]

[Cites] J Exp Med. 2000 Feb 21;191(4):631-40 [10684855.001]

[Cites] Oncogene. 2000 Feb 10;19(6):745-53 [10698492.001]

[Cites] Genes Dev. 2000 Aug 1;14(15):1920-32 [10921906.001]

[Cites] Oncogene. 2001 Jan 4;20(1):1-9 [11244500.001]

[Cites] Nat Cell Biol. 2001 Aug;3(8):708-14 [11483955.001]

[Cites] J Biol Chem. 2001 Oct 19;276(42):39103-6 [11495919.001]

[Cites] Br J Haematol. 2001 Nov;115(2):287-97 [11703323.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):207-12 [11756662.001]

[Cites] J Biol Chem. 2002 Mar 29;277(13):11156-64 [11799127.001]

[Cites] J Biol Chem. 2002 Jul 12;277(28):25446-56 [11948183.001]

[Cites] J Cell Sci. 2002 Aug 15;115(Pt 16):3319-30 [12140263.001]

[Cites] J Biol Chem. 2002 Nov 15;277(46):44557-65 [12213825.001]

[Cites] EMBO J. 2003 Feb 17;22(4):882-92 [12574124.001]

[Cites] J Biol Chem. 2003 Mar 14;278(11):9609-19 [12524424.001]

[Cites] Blood Rev. 2003 Jun;17(2):71-97 [12642121.001]

[Cites] J Biol Chem. 2003 May 2;278(18):15958-65 [12595526.001]

[Cites] J Biol Chem. 2003 Aug 29;278(35):33416-21 [12810706.001]

[Cites] Nucleic Acids Res. 2003 Sep 15;31(18):5356-67 [12954772.001]

[Cites] J Biol Chem. 2003 Sep 19;278(38):36959-65 [12857754.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10635-40 [12953102.001]

[Cites] Mol Cell Biol. 2003 Oct;23(20):7108-21 [14517282.001]

[Cites] EMBO J. 2003 Nov 3;22(21):5806-16 [14592978.001]

[Cites] Cancer Res. 2003 Dec 1;63(23):8271-7 [14678985.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4100-5 [15016915.001]

[Cites] Nature. 1990 Oct 11;347(6293):558-61 [2170850.001]

[Cites] Cell. 1991 Aug 23;66(4):663-74 [1652368.001]

[Cites] Cell. 1993 Aug 13;74(3):423-31 [8394219.001]

[Cites] Cell. 1994 Jan 28;76(2):333-43 [8293467.001]

[Cites] Cell. 1994 Jan 28;76(2):345-56 [8293468.001]

[Cites] EMBO J. 1994 Mar 1;13(5):1073-83 [8131741.001]

[Cites] Genes Dev. 1994 Nov 15;8(22):2781-91 [7958933.001]

[Cites] EMBO J. 1996 Jun 3;15(11):2771-80 [8654374.001]

[Cites] Cell. 1997 Jun 27;89(7):1067-76 [9215629.001]

[Cites] Mol Cell Biol. 1997 Nov;17(11):6609-17 [9343424.001]

[Cites] Nature. 1998 Feb 19;391(6669):811-4 [9486654.001]

[Cites] Br J Cancer. 1999 Mar;79(7-8):1240-8 [10098766.001]

[Cites] EMBO J. 1999 Jul 1;18(13):3702-11 [10393185.001]

[Cites] Genes Dev. 1999 Aug 1;13(15):1918-23 [10444590.001]

[Cites] J Cell Biol. 1999 Oct 18;147(2):221-34 [10525530.001]

[Cites] Mol Cell Biol. 2005 Jan;25(1):499-511 [15601869.001]

(PMID = 19690170.001).

[ISSN] 1083-351X

[Journal-full-title] The Journal of biological chemistry

[ISO-abbreviation] J. Biol. Chem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / CCAAT-Enhancer-Binding Protein-beta; 0 / DAXX protein, human; 0 / Nuclear Proteins; 5688UTC01R / Tretinoin; EC 2.3.1.48 / p300-CBP Transcription Factors

[Other-IDs] NLM/ PMC2781424

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia.

Arsenic trioxide (As2O3) is an effective drug for treatment of acute promyelocytic leukemia (APL) and malignant tumors.

Cell lines and cell strains of leukemia and solid cancer cells were treated with different concentrations of As2O3, and the concentrations were compared to apoptosis detected by FITC-annexin V and propidium iodide (PI) double staining.

These results indicate that different leukemia and solid carcinoma cell lines have different intracellular arsenic concentrations, which correlate with different sensitivities to As2O3 in clinical treatment.

Novel techniques by maintaining continuous low but effective arsenic levels inside the target leukemic cells in APL may improve the complete remission rate and overall survival with minimum cost and drug toxicity.

[MeSH-major] Arsenicals / pharmacokinetics. Leukemia, Promyelocytic, Acute / pathology. Oxides / pharmacokinetics

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2005 Wiley-Liss, Inc.

(PMID = 15682419.001).

[ISSN] 0361-8609

[Journal-full-title] American journal of hematology

[ISO-abbreviation] Am. J. Hematol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment of newly diagnosed patients with acute promyelocytic leukemia with modified spanish treatment protocol.

The results of treatment of acute promyelocytic leukemia, when combination ATRA + chemotherapy is used in induction and maintainance therapy and risk adapted strategy applied in consolidation, improved at present time.

29 (90.6%) patients achieved complete hematologic remission, 2 (6.3 %) molecular relapses were observed, death was observed in 4 patients (12.5%).

Current recommendations for treatment with risk-adapted strategy for patients with newly diagnosed acute promyelocytic leukemia resulted in our patients group to comparable outcome and good compliance like in other published studies.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20353280.001).

[ISSN] 0028-2685

[Journal-full-title] Neoplasma

[ISO-abbreviation] Neoplasma

[Language] eng

[Publication-type] Journal Article

[Publication-country] Slovakia

[Chemical-registry-number] 5688UTC01R / Tretinoin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.

Arsenic trioxide (ATO) induces remission in 85% of adults with refractory acute promyelocytic leukemia (APL).

We conducted a phase 1 trial of ATO in children (median age 13 y, range, 2-19) with refractory leukemia.

Patients with APL (n=13) received 0.15 mg/kg per day, and patients with other types of leukemia received 0.15 mg/kg per day (n=2) or 0.2 mg/kg per day (n=4).

[MeSH-major] Antineoplastic Agents / pharmacokinetics. Arsenicals / pharmacokinetics. Leukemia, Promyelocytic, Acute / drug therapy. Lymphoma / drug therapy. Oxides / pharmacokinetics

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Lymphoma.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]

[Cites] Leuk Lymphoma. 2004 Dec;45(12):2387-401 [15621751.001]

[Cites] J Clin Oncol. 2000 Jul;18(13):2620-5 [10893295.001]

[Cites] Blood. 2001 Jul 15;98(2):266-71 [11435292.001]

[Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]

[Cites] Eur J Clin Pharmacol. 2002 Nov;58(8):521-6 [12451429.001]

[Cites] J Environ Sci Health A Tox Hazard Subst Environ Eng. 2003 Jan;38(1):165-83 [12635825.001]

[Cites] Cancer. 2003 May 1;97(9):2218-24 [12712474.001]

[Cites] J Biol Chem. 2003 Aug 22;278(34):31998-2004 [12767976.001]

[Cites] J Clin Oncol. 2003 Oct 1;21(19):3609-15 [14512391.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4578-83 [15070760.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]

[Cites] Blood. 2004 May 1;103(9):3496-502 [14701702.001]

[Cites] Clin Chem. 1992 Dec;38(12):2479-83 [1458588.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3978-83 [9108090.001]

[Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]

[Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]

[Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):124-33 [9450572.001]

[Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]

[Cites] Cancer Res. 1999 Jul 1;59(13):3053-8 [10397243.001]

[Cites] Blood. 1999 Sep 15;94(6):2102-11 [10477740.001]

[Cites] Blood. 2000 Jan 1;95(1):90-5 [10607690.001]

(PMID = 17959855.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Databank-accession-numbers] ClinicalTrials.gov/ NCT00020111

[Grant] United States / NCI NIH HHS / CA / U01 CA097452; United States / NCI NIH HHS / CA / UM1 CA097452; United States / NCI NIH HHS / CA / CA97452; United States / Intramural NIH HHS / /

[Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide

[Other-IDs] NLM/ PMC2200837

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic significance of flow cytometric immunophenotyping in acute myeloid leukemia.

The prognostic significance of flow cytometric immunophenotyping (FCI) in acute myeloid leukemia (AML) has been controversial.

Among those, 78 cases were in remission (M:F=44/34; mean age of 48.9 years) and 131 had relapse (M:F=71/60; mean age of 51.3 years).

The expression of CD34, HLA-DR or a combination of both was significantly different between the remission and relapse groups for all AML as well as AML without t(15;17).

Complex cytogenetic abnormalities were more likely associated with relapse group than with remission group, but were not statistically significant after excluding AML with t(15;17).

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 1994 Aug 15;84(4):1220-5 [8049437.001]

[Cites] Leuk Res. 1994 Jan;18(1):29-35 [8289464.001]

[Cites] Haematologica. 1993 May-Jun;78(3):151-5 [7690733.001]

[Cites] Blood. 1993 May 1;81(9):2399-405 [7683218.001]

[Cites] Leukemia. 1992 Nov;6(11):1203-9 [1279324.001]

[Cites] Leukemia. 1992 May;6(5):393-9 [1375696.001]

[Cites] Am J Clin Pathol. 1992 Oct;98(4):430-6 [1415023.001]

[Cites] Blood. 1991 May 15;77(10):2242-50 [1709379.001]

[Cites] Br J Haematol. 1989 Jun;72(2):161-6 [2757962.001]

[Cites] Hematol Oncol. 1990 Jan-Feb;8(1):47-58 [2404842.001]

[Cites] J Clin Oncol. 1990 Mar;8(3):423-30 [2307987.001]

[Cites] Haematologica. 2004 May;89(5):528-40 [15136215.001]

[Cites] Leuk Res. 2004 Jan;28(1):43-8 [14630079.001]

[Cites] Leukemia. 2003 Apr;17(4):707-15 [12682628.001]

[Cites] Arch Pathol Lab Med. 2003 Jan;127(1):42-8 [12521365.001]

[Cites] Haematologica. 2002 Nov;87(11):1135-40 [12414342.001]

[Cites] Am J Clin Pathol. 2002 Oct;118(4):560-6 [12375643.001]

[Cites] Am J Hematol. 2001 Oct;68(2):69-74 [11559944.001]

[Cites] Haematologica. 2001 Aug;86(8):801-6 [11522535.001]

[Cites] Cancer Res. 2001 Jun 1;61(11):4483-9 [11389079.001]

[Cites] Semin Hematol. 2001 Apr;38(2):124-38 [11309694.001]

[Cites] Blood. 2000 Aug 1;96(3):870-7 [10910899.001]

[Cites] Am J Clin Pathol. 2000 Feb;113(2):193-200 [10664621.001]

[Cites] Leukemia. 2007 Jun;21(6):1204-11 [17410192.001]

[Cites] Ann Hematol. 2007 May;86(5):311-27 [17375301.001]

[Cites] Leuk Res. 2007 Jan;31(1):113-6 [16730795.001]

[Cites] Leukemia. 2006 May;20(5):888-91 [16525493.001]

[Cites] Neoplasma. 2006;53(2):155-60 [16575472.001]

[Cites] Am J Hematol. 2006 Apr;81(4):227-35 [16550517.001]

[Cites] Cancer. 2006 Feb 15;106(4):839-47 [16419072.001]

[Cites] Neoplasma. 2005;52(5):402-10 [16151585.001]

[Cites] Leuk Res. 2005 Oct;29(10):1109-16 [16095690.001]

[Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]

[Cites] Am J Hematol. 1998 Aug;58(4):278-84 [9692390.001]

[Cites] Leukemia. 1998 Jul;12(7):1056-63 [9665190.001]

[Cites] Am J Clin Pathol. 1998 Feb;109(2):211-20 [9583894.001]

[Cites] Blood. 1998 May 1;91(9):3401-13 [9558399.001]

[Cites] Leuk Res. 1997 Oct;21(10):985-95 [9403009.001]

[Cites] Leuk Res. 1997 Jul;21(7):603-7 [9301680.001]

[Cites] Blood. 1997 Aug 15;90(4):1643-8 [9269784.001]

[Cites] Leukemia. 1997 Nov;11(11):1878-86 [9369421.001]

[Cites] Baillieres Clin Haematol. 1996 Mar;9(1):87-105 [8730552.001]

[Cites] Blood. 1995 Oct 15;86(8):3097-108 [7579404.001]

[Cites] Blood. 1995 Apr 15;85(8):2147-53 [7536492.001]

[Cites] Leuk Lymphoma. 1995 Mar;17(1-2):111-9 [7539657.001]

[Cites] Leukemia. 1994 May;8(5):823-6 [7514247.001]

[Cites] Leuk Lymphoma. 1994;13 Suppl 1:81-5 [7521238.001]

[Cites] Leukemia. 1994 Mar;8(3):388-94 [7907393.001]

[Cites] J Cancer Res Clin Oncol. 1994;120(9):553-7 [8045921.001]

(PMID = 18784805.001).

[ISSN] 1936-2625

[Journal-full-title] International journal of clinical and experimental pathology

[ISO-abbreviation] Int J Clin Exp Pathol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC2480555

[Keywords] NOTNLM ; Flow cytometric immunophenotyping / acute myeloid leukemia / acute promyelocytic leukemia / chromosome translocation / cytogenetics / prognosis

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death.

Acute promyelocytic leukemia (APL) is efficiently treated with a cell differentiation inducer, all-trans retinoic acid (ATRA).

Such long-term low-dose combinatorial therapy strategies, developed also to avoid acute side effects, reinforce the notion that the antitelomerase strategy, based on a combination of active agents, should now be considered and evaluated not only in APL but also in other malignancies.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. DNA-Binding Proteins / metabolism. Drug Resistance, Neoplasm. Leukemia, Promyelocytic, Acute / drug therapy. Telomerase / metabolism

[MeSH-minor] Arsenicals / administration & dosage. Humans. Neoplasm Proteins / metabolism. Oncogene Proteins, Fusion / metabolism. Oxides / administration & dosage. Remission Induction. Telomere / metabolism. Tretinoin / administration & dosage. Tumor Cells, Cultured

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16107885.001).

[ISSN] 0887-6924

[Journal-full-title] Leukemia

[ISO-abbreviation] Leukemia

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Arsenicals; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; EC 2.7.7.49 / Telomerase; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid.

[MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Cardiomyopathies / complications. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use

[MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Drug Therapy, Combination. Echocardiography. Humans. Male. Middle Aged. Oncogene Proteins, Fusion / genetics. Oxides / therapeutic use. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome

Genetic Alliance. consumer health - Cardiomyopathy.

MedlinePlus Health Information. consumer health - Cardiomyopathy.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17136541.001).

[ISSN] 1432-0584

[Journal-full-title] Annals of hematology

[ISO-abbreviation] Ann. Hematol.

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] Germany

[Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / gemtuzumab; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Present status in studying immunotherapy for acute leukemia and its perspective--Editorial].

One of the important approaches for further prolonging remission duration and eradicating minimal residual disease in acute leukemia is immunotherapy.

Four kinds of immunotherapy for acute leukemia are under investigation:.

(1) monoclonal antibodies, among them, Mylotarg (cytotoxic antibiotic calicheamicin linked to CD33 Mab) is given for the treatment of refractory or relapsed acute myeloid leukemia and molecular relapse in acute promyelocytic leukemia with good results, Campath-1H (antiCD52 Mab) is administered in the treatment of prolymphocytic leukemia and Rituximab (anti-CD20 Mab) in B-PLL with high complete remission rates.

Other Mabs under preclinical and clinical trials include anti-IL-2 receptor Mab for the treatment of acute T lymphocytic leukemia, anti-220 kD Mab-6G7 for acute leukemias, recombinant immune toxin BL22 (anti-CD22) for hairy cell leukemia and Mabs labeled with radio-isotopes for different types of acute leukemias;.

(4) leukemia vaccines of several different formulations including antigen-specific, leukemia cell-based, leukemia antigen-pulsed dendritic cell (DC) and leukemia-derived DC vaccines, the latter two formulations are more attractive.

In conclusion, up to now, the most effective example of immunotherapy in acute leukemia is provided by the administration of Mabs, and the majority of other approaches in immunotherapy for acute leukemia although promising, need further studies.

MedlinePlus Health Information. consumer health - Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15854271.001).

[ISSN] 1009-2137

[Journal-full-title] Zhongguo shi yan xue ye xue za zhi

[ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi

[Language] CHI

[Publication-type] Editorial; English Abstract

[Publication-country] China

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cancer Vaccines

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Aplastic anemia surfacing after treatment of acute promyelocytic leukemia: The Dameshek riddle.

[MeSH-major] Anemia, Aplastic / chemically induced. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Humans. Remission Induction

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Anemia.

Genetic Alliance. consumer health - Aplastic Anemia.

MedlinePlus Health Information. consumer health - Aplastic Anemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20040908.001).

[ISSN] 1543-0790

[Journal-full-title] Clinical advances in hematology & oncology : H&O

[ISO-abbreviation] Clin Adv Hematol Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.

PURPOSE: To retrospectively determine the outcome of acute promyelocytic leukemia (APL) patients who underwent autologous or allogeneic stem-cell transplantation (SCT) during second complete remission.

PATIENTS AND METHODS: Of 122 relapsing patients included in two successive multicenter APL trials who achieved hematological second complete remission (generally after a salvage regimen of all-trans-retinoic acid [ATRA] combined with chemotherapy), 73 (60%) received allogeneic (n = 23) or autologous (n = 50) SCT.

CONCLUSION: These retrospective data suggest that autologous SCT is very effective in APL relapsing after treatment with ATRA if performed in molecular remission.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Promyelocytic, Acute / therapy. Salvage Therapy. Stem Cell Transplantation. Tretinoin / administration & dosage

[MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Rate. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Transplantation.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15534358.001).

[ISSN] 0732-183X

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 5688UTC01R / Tretinoin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Long-term results of combined treatment of acute promyelocytic leukemia in children and adolescents with gene therapy].

AIM: To analyse the results of treatment of children and adolescents with acute promyelocytic leukemia (APL) including polychemotherapy and ATRA (protocols APL 93, 98 and 2003).

RESULTS: For prognosis of the disease important are initial characteristics of the patient and the time of the tumor regress assessed by molecular methods--establishment of molecular remission and molecular recurrence.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Receptors, Retinoic Acid / genetics. Transcription, Genetic / drug effects

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17802786.001).

[ISSN] 0040-3660

[Journal-full-title] Terapevticheskiĭ arkhiv

[ISO-abbreviation] Ter. Arkh.

[Language] rus

[Publication-type] English Abstract; Journal Article

[Publication-country] Russia (Federation)

[Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Therapy-related myelodysplastic syndrome following acute promyelocytic leukemia and biphenotypic acute leukemia following stem cell transplantation in the same patient.

Therapy-related myelodysplastic syndrome in patients with acute promyelocytic leukemia is a rare event and the prognosis is poor.

We present a young patient with acute promyelocytic leukemia who developed myelodysplastic syndrome 52 months after complete remission.

She underwent allogeneic peripheral blood stem cell transplantation but relapsed with biphenotypic leukemia after five months.

To our knowledge, this is the first case to relapse with acute biphenotypic leukemia after allogeneic peripheral stem cell transplantation for therapy-related myelodysplastic syndrome following acute promyelocytic leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27263623.001).

[ISSN] 1300-7777

[Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology

[ISO-abbreviation] Turk J Haematol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Turkey

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.

BACKGROUND: From 20% to 30% of patients with acute promyelocytic leukemia (APL) who are treated with all-trans retinoic acid (ATRA) develop recurrent disease.

Patients received ATO 0.15 mg/kg intravenously until they achieved a bone marrow complete remission (CR).

All 7 evaluable patients achieved molecular remission.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Neoplasm Recurrence, Local / drug therapy

[MeSH-minor] Adult. Aged. Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Arsenicals / administration & dosage. Humans. Middle Aged. Oxides / administration & dosage. Remission Induction. Treatment Outcome. Tretinoin / administration & dosage

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2007 American Cancer Society.

(PMID = 17326049.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Arsenicals; 0 / Oxides; 0 / gemtuzumab; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.

In 1997-2003, a protocol for treatment of acute myeloid leukaemia (AML) (except promyelocytic leukaemia) was activated in four Swedish health care regions covering 50% of the national population.

Induction failures accounted for 55 patients; 16 early deaths eight of whom had white blood cell (WBC) >100 at diagnosis, and 39 refractory disease.

Thus, complete remission (CR) rate was 80%.

Median survival time from diagnosis in the whole group was 27 months and 4-yr overall survival (OS) rate was 44%.

(ii) a risk-adapted therapy aiming at early allogeneic SCT in patients with a high risk of relapse is hampered by induction deaths, refractory disease, and early relapses; and (iii) high WBC count at diagnosis is confirmed as a strong risk factor for early death but not for relapse.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / therapy. Population Surveillance. Stem Cell Transplantation / adverse effects

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19385987.001).

[ISSN] 1600-0609

[Journal-full-title] European journal of haematology

[ISO-abbreviation] Eur. J. Haematol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Real-time PCR analysis of PML-RAR alpha in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy.

BACKGROUND: Recently, patients with acute promyelocytic leukaemia (APL) have experienced significant clinical gains after treatment with arsenic trioxide.

PATIENTS AND METHODS: Of 95 newly diagnosed APL patients, 85 patients who achieved complete remission (CR) were sequentially evaluated during a 4-60 month period by conventional RT-PCR.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16831853.001).

[ISSN] 0923-7534

[Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology

[ISO-abbreviation] Ann. Oncol.

[Language] ENG

[Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / Protein Isoforms; 0 / Recombinant Fusion Proteins; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; EC 1.1.1.49 / Glucosephosphate Dehydrogenase; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity.

Arsenic trioxide, as a single agent, has proven efficacy in inducing molecular remission in patients with acute promyelocytic leukemia (APL).

Complete hematologic remission was achieved in 86.1%.

Patients presenting with a white blood cell (WBC) count lower than 5 x 10(9)/L and a platelet count higher than 20 x 10(9)/L at diagnosis (n = 22 [30.6%]) have an excellent prognosis with this regimen (EFS, OS, and DFS of 100%).

After remission induction, this regimen was administered on an outpatient basis.

Additionally, this regimen has minimal toxicity and can be administered on an outpatient basis after remission induction.

[MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use

[MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Partial Thromboplastin Time. Platelet Count. Remission Induction. Survival Analysis. Treatment Outcome

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16352810.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group.

Acute promyelocytic leukemia (APL) is the most curable subtype of acute myeloid leukemia.

Second complete remission (CR2) can be easily achieved with several therapeutic options even after relapse.

Three autografted patients and one allografted patient relapsed, and one autografted patient and five allografted patients died without leukemia relapse.

[MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Promyelocytic, Acute / therapy. Neoplasm Recurrence, Local / therapy

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 1997 Aug 1;90(3):1321-5 [9242568.001]

[Cites] Blood. 1997 Aug 1;90(3):967-73 [9242525.001]

[Cites] J Clin Oncol. 1998 Jan;16(1):78-85 [9440726.001]

[Cites] Blood. 2002 Dec 15;100(13):4298-302 [12393590.001]

[Cites] Blood. 2002 Feb 1;99(3):759-67 [11806975.001]

[Cites] Haematologica. 2004 May;89(5):621-2 [15136233.001]

[Cites] Ann Hematol. 1997 Nov-Dec;75(5-6):195-200 [9433375.001]

[Cites] Leukemia. 2000 Jun;14(6):1006-13 [10865965.001]

[Cites] Blood. 1998 Aug 15;92(4):1073-90 [9694694.001]

[Cites] J Clin Oncol. 2005 Apr 1;23(10):2396-410 [15800332.001]

[Cites] Best Pract Res Clin Haematol. 2002 Mar;15(1):137-58 [11987921.001]

[Cites] J Clin Oncol. 2005 Jan 1;23(1):120-6 [15534358.001]

[Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]

[Cites] Int J Hematol. 2000 Dec;72(4):470-3 [11197214.001]

(PMID = 18301963.001).

[ISSN] 0925-5710

[Journal-full-title] International journal of hematology

[ISO-abbreviation] Int. J. Hematol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Japan

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia.

The use of all-trans retinoic acid (ATRA) has markedly improved the survival of patients with acute promyelocytic leukemia (APL), making it potentially curable.

However, the identification of prognostic markers predictive of durable remission remains an important aspect in risk-adjusted treatment algorithms.

[MeSH-major] Cyclin-Dependent Kinase Inhibitor p15 / genetics. DNA Methylation. Leukemia, Promyelocytic, Acute / genetics

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16753865.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Chemical-registry-number] 0 / CDKN2B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p15

[Number-of-references] 71

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Arsenic trioxide (ATO, As2O3) is emerging as a front line agent for treatment of acute promyelocytic leukemia with giving a complete remission rate of 83-95%.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. DOXORUBICIN .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17031934.001).

[ISSN] 0002-7863

[Journal-full-title] Journal of the American Chemical Society

[ISO-abbreviation] J. Am. Chem. Soc.

[Language] eng

[Grant] United States / NIGMS NIH HHS / GM / GM 054111; United States / NCI NIH HHS / CA / P30 CA 060553; United States / NCI NIH HHS / CA / U54 CA 119341

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Capsules; 0 / Lipids; 0 / Liposomes; 0 / Oxides; 80168379AG / Doxorubicin; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.

PURPOSE OF REVIEW: While arsenic has long been known as a poison and environmental carcinogen, its dramatic effect in the treatment of acute promyelocytic leukemia (APL) has made its mechanism of action a topic of intense interest.

ATO) for 30 to 40 days can lead to complete remission in about 85% of patients with newly diagnosed or relapsed APL.

The combination of all-trans retinoic acid and ATO in patients with newly diagnosed APL has yielded more durable remission than monotherapy.

[MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15604884.001).

[ISSN] 1065-6251

[Journal-full-title] Current opinion in hematology

[ISO-abbreviation] Curr. Opin. Hematol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / Reactive Oxygen Species; S7V92P67HO / arsenic trioxide

[Number-of-references] 63

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

A DNA vaccine encoding PML-RAR alpha fusion gene is thought to be a promising approach for acute promyelocytic leukemia patients to enhance immune responses after attaining complete remission.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20423569.001).

[ISSN] 1607-8454

[Journal-full-title] Hematology (Amsterdam, Netherlands)

[ISO-abbreviation] Hematology

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Interleukin-2; 0 / Oncogene Proteins, Fusion; 0 / Recombinant Fusion Proteins; 0 / Vaccines, DNA; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 82115-62-6 / Interferon-gamma

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Successful mobilization of peripheral blood stem cells in an acute promyelocytic leukemia patient after gemtuzumab ozogamicin.

[MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Hematopoietic Stem Cell Mobilization. Leukemia, Promyelocytic, Acute / therapy. Peripheral Blood Stem Cell Transplantation. Transplantation Conditioning

[MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Humans. Middle Aged. Remission Induction. Transplantation, Autologous

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17502892.001).

[ISSN] 0268-3369

[Journal-full-title] Bone marrow transplantation

[ISO-abbreviation] Bone Marrow Transplant.

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] England

[Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

To investigate the biological characteristics of the variant translocation der ins (17;15) in a patient with acute promyelocytic leukemia (APL), the conventional G-banding technique, interphase fluorescence in situ hybridization (int-FISH), RT-PCR, gene scanning, gene sequence and flow cytometry were performed.

This patient got complete remission by using combined chemotherapy, and survives with continuous complete remission during following up for 1 year.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19549359.001).

[ISSN] 1009-2137

[Journal-full-title] Zhongguo shi yan xue ye xue za zhi

[ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi

[Language] CHI

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] China

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Herbo-mineral ayurvedic treatment in a high risk acute promyelocytic leukemia patient with second relapse: 12 years follow up.

Initially treated with ATRA, he achieved hematological remission on day 60, but cytogenetically the disease persisted.

The patient received induction and consolidated chemotherapy with Daunorubicin and Cytarabine combination from 12.01.96 to 14.05.96, following which he achieved remission.

The patient was given two cycles of chemotherapy with Idarubicine and Etoposide, after which he achieved remission.

The patient achieved complete disease remission with the alternative treatment without any adverse side effects.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2009 Feb 26;113(9):1875-91 [18812465.001]

[Cites] Indian J Cancer. 2009 Jan-Mar;46(1):1-4 [19282559.001]

[Cites] Br J Haematol. 1999 Oct;107(1):69-79 [10520026.001]

[Cites] Leukemia. 2001 Apr;15(4):670-2 [11368376.001]

[Cites] Pharmacoepidemiol Drug Saf. 2002 Dec;11(8):671-6 [12512243.001]

[Cites] Biol Pharm Bull. 2006 May;29(5):1022-7 [16651738.001]

[Cites] Best Pract Res Clin Haematol. 2007 Mar;20(1):57-65 [17336255.001]

[Cites] Semin Oncol. 2008 Aug;35(4):401-9 [18692690.001]

(PMID = 21547051.001).

[ISSN] 0976-2809

[Journal-full-title] Journal of Ayurveda and integrative medicine

[ISO-abbreviation] J Ayurveda Integr Med

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Other-IDs] NLM/ PMC3087364

[Keywords] NOTNLM ; Ayurveda / herbo-mineral / relapse acute promyelocytic leukemia

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Therapeutic effects of combination of arsenic trioxide with low-dose all-trans retinoic acid on induction of remission acute promyeloeytic leukemia].

OBJECTIVE: To observe the therapeutic efficacy and side effects of arsenic trioxide (As2O3)combined with low-dose all-trans retinoic acid (ATRA) on remission induction in newly-diagnosed and relapsed patients with acute promyeloeytic leukemia (APL).

The complete remission (CR) rate, period to CR, incidence of early death and side effects were observed in the three groups.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Adolescent. Adult. Arsenicals / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Oxides / administration & dosage. Remission Induction. Treatment Outcome. Tretinoin / administration & dosage

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16029564.001).

[ISSN] 0376-2491

[Journal-full-title] Zhonghua yi xue za zhi

[ISO-abbreviation] Zhonghua Yi Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

Fetal liver tyrosine kinase 3 (FLT3) internal tandem duplications (ITDs) are powerful adverse prognostic indicators for relapse in acute myeloid leukemia (AML) but the most efficacious therapy for FLT3/ITD(+) patients is currently unknown.

We evaluated outcome according to FLT3/ITD status in 1135 adult patients treated according to United Kingdom Medical Research Council (UK MRC) AML protocols: 141 received an autograft, and 170 received a matched sibling allograft in first complete remission (CR).

[MeSH-major] Biomarkers, Tumor. Gene Duplication. Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation. fms-Like Tyrosine Kinase 3

[MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Great Britain. Humans. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / metabolism. Leukemia, Promyelocytic, Acute / therapy. Male. Meta-Analysis as Topic. Middle Aged. Prognosis. Randomized Controlled Trials as Topic. Recurrence. Transplantation, Autologous. Transplantation, Homologous

Genetic Alliance. consumer health - Acute Myelocytic Leukemia.

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Leukemia, Myeloid.

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Blood. 2007 Mar 1;109(5):2264-5; author reply 2265 [17312001.001]

[CommentIn] Blood. 2006 Jul 1;108(1):400; author reply 400-1 [16790584.001]

(PMID = 16076872.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia.

PURPOSE: The Forkhead transcription factors (FOXO) are tumor suppressor genes regulating differentiation, metabolism, and apoptosis that functionally interact with signal transduction pathways shown to be deregulated and prognostic in acute myelogenous leukemia (AML).

EXPERIMENTAL DESIGN: We used reverse-phase protein array methods to measure the level of total and phosphoprotein expression of FOXO3A, in leukemia-enriched protein samples from 511 newly diagnosed AML patients.

Levels of total FOXO3A were higher at relapse compared with diagnosis.

Patients with High levels of pFOXO3A or PT-FOXO3A had higher rates of primary resistance and shorter remission durations, which combine to cause an inferior survival experience (P = 0.0002).

[MeSH-major] Forkhead Transcription Factors / metabolism. Leukemia, Myeloid, Acute / metabolism. Leukemia, Promyelocytic, Acute / metabolism. Neoplasm Proteins / metabolism

[MeSH-minor] Adolescent. Adult. Aged. Antigens, CD34 / metabolism. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Phosphorylation. Prognosis. Protein Array Analysis. Remission Induction. Survival Rate. Young Adult

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Trends Mol Med. 2008 May;14(5):219-27 [18403263.001]

[Cites] Breast Cancer Res. 2008;10(1):R21 [18312651.001]

[Cites] Eur J Haematol. 2008 Aug;81(2):83-93 [18363870.001]

[Cites] Mol Cell Biol. 2008 Oct;28(19):5886-98 [18644865.001]

[Cites] Blood. 2009 Jan 1;113(1):154-64 [18840713.001]

[Cites] Cell Cycle. 2008 Dec 15;7(24):3829-39 [19066462.001]

[Cites] Clin Cancer Res. 2009 Feb 1;15(3):752-7 [19188143.001]

[Cites] Bioinformatics. 2009 Jun 1;25(11):1384-9 [19336447.001]

[Cites] Leuk Res. 2009 Dec;33(12):1706-9 [19457552.001]

[Cites] Cancer Invest. 2009 Jan;27(1):52-9 [19160093.001]

[Cites] Genes Dev. 2000 Jan 15;14(2):142-6 [10702024.001]

[Cites] Mol Cell Biol. 2001 Feb;21(3):952-65 [11154281.001]

[Cites] Biochem J. 2001 May 1;355(Pt 3):597-607 [11311120.001]

[Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]

[Cites] Trends Biochem Sci. 2002 Jul;27(7):352-60 [12114024.001]

[Cites] Cancer Cell. 2002 Jul;2(1):81-91 [12150827.001]

[Cites] J Biol Chem. 2003 Feb 21;278(8):5871-82 [12488318.001]

[Cites] Cell. 2004 Apr 16;117(2):225-37 [15084260.001]

[Cites] Oncogene. 2004 Apr 22;23(19):3338-49 [14981546.001]

[Cites] Mol Cell. 2004 May 21;14(4):416-8 [15149589.001]

[Cites] Cancer Res. 1994 Jun 1;54(11):2869-72 [8187070.001]

[Cites] J Histochem Cytochem. 1996 Dec;44(12):1353-62 [8985127.001]

[Cites] Oncogene. 1997 Jan 16;14(2):195-202 [9010221.001]

[Cites] Genomics. 1998 Jan 15;47(2):187-99 [9479491.001]

[Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]

[Cites] BMC Neurosci. 2004 Nov 29;5:48 [15569384.001]

[Cites] Cell Cycle. 2005 Jul;4(7):908-13 [15917664.001]

[Cites] Oncogene. 2005 Nov 14;24(50):7410-25 [16288288.001]

[Cites] Cell. 2006 Jun 2;125(5):987-1001 [16751106.001]

[Cites] Exp Gerontol. 2006 Aug;41(8):709-17 [16806782.001]

[Cites] Blood. 2006 Oct 1;108(7):2358-65 [16763210.001]

[Cites] Science. 2006 Oct 13;314(5797):294-7 [17038621.001]

[Cites] Mol Cancer Ther. 2006 Oct;5(10):2512-21 [17041095.001]

[Cites] Cell. 2007 Jan 26;128(2):309-23 [17254969.001]

[Cites] Cell. 2007 Jan 26;128(2):325-39 [17254970.001]

[Cites] Cell Death Differ. 2007 Mar;14(3):534-47 [16888645.001]

[Cites] Bioinformatics. 2007 Aug 1;23(15):1986-94 [17599930.001]

[Cites] Nat Rev Cancer. 2007 Nov;7(11):847-59 [17943136.001]

[Cites] Cancer Sci. 2007 Dec;98(12):1949-58 [17900262.001]

[Cites] Oncogene. 2007 Nov 1;26(50):7081-91 [17496928.001]

[Cites] Nucleic Acids Res. 2007;35(20):6984-94 [17940099.001]

[Cites] Nat Cell Biol. 2008 Feb;10(2):138-48 [18204439.001]

[Cites] Cell Stem Cell. 2007 Jun 7;1(1):101-12 [18371339.001]

[Cites] Oncogene. 2008 Apr 7;27(16):2276-88 [18391970.001]

[Cites] Oncogene. 2008 Apr 7;27(16):2351-63 [18391977.001]

[Cites] Expert Opin Ther Targets. 2008 Jul;12(7):905-16 [18554157.001]

(PMID = 20215543.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P01 CA108631

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD34; 0 / FOXO3 protein, human; 0 / Forkhead Transcription Factors; 0 / Neoplasm Proteins

[Other-IDs] NLM/ NIHMS378348; NLM/ PMC3385949

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A case of acute promyelocytic leukemia showing transient thrombocytosis caused by increased interleukin-6 and thrombopoietin after treatment with all-trans retinoic acid and chemotherapy.

A patient with acute promyelocytic leukemia(APL)treated with all-trans retinoic acid(ATRA)and chemotherapy for remission induction developed marked thrombocytosis after bone marrow recovery.

Thrombocytosis also occurred after post remission chemotherapies, although the degree of thrombocytosis gradually decreased.

However, the plasma level of TPO was markedly elevated at the nadir after post remission chemotherapy.

[MeSH-major] Antineoplastic Agents / therapeutic use. Interleukin-6 / blood. Leukemia, Promyelocytic, Acute / drug therapy. Thrombocytosis / drug therapy. Thrombopoietin / blood. Tretinoin / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19461187.001).

[ISSN] 0385-0684

[Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy

[ISO-abbreviation] Gan To Kagaku Ryoho

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-6; 5688UTC01R / Tretinoin; 9014-42-0 / Thrombopoietin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A complex, four-way variant t(15;17) in acute promyelocytic leukemia.

Complex variant 15;17 translocations are increasingly recognized in acute promyelocytic leukemia (APL).

A complete remission was attained with a course of conventional chemotherapy including ATRA.

[MeSH-major] Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 17. Leukemia, Promyelocytic, Acute / genetics. Translocation, Genetic

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16737919.001).

[ISSN] 0165-4608

[Journal-full-title] Cancer genetics and cytogenetics

[ISO-abbreviation] Cancer Genet. Cytogenet.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Arsenic-based compounds have become accepted agents for cancer therapy providing high rates of remission of some cancers such as acute promyelocytic leukemia (APL).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Biol Chem. 2003 Sep 26;278(39):37832-9 [12853461.001]

[Cites] Mol Cancer Res. 2003 Jul;1(9):682-9 [12861054.001]

[Cites] J Biol Chem. 1960 Feb;235:492-5 [13831697.001]

[Cites] Biochemistry. 2003 Sep 30;42(38):11214-25 [14503871.001]

[Cites] Curr Mol Med. 2003 Nov;3(7):643-51 [14601638.001]

[Cites] Oncogene. 2004 Feb 12;23(6):1239-47 [14647451.001]

[Cites] Chem Res Toxicol. 2004 Feb;17(2):243-9 [14967012.001]

[Cites] J Biol Chem. 2004 May 21;279(21):22284-93 [14985369.001]

[Cites] Biochem Biophys Res Commun. 2004 Apr 16;316(4):1178-85 [15044109.001]

[Cites] Circ Res. 2004 Jun 11;94(11):1483-91 [15117824.001]

[Cites] J Inorg Biochem. 2004 Jun;98(6):1151-9 [15149827.001]

[Cites] J Biol Chem. 2004 Jul 30;279(31):32700-8 [15161912.001]

[Cites] Blood. 2005 Feb 1;105(3):1198-203 [15231573.001]

[Cites] J Biol Chem. 2004 Oct 1;279(40):41975-84 [15280382.001]

[Cites] Leuk Lymphoma. 2004 May;45(5):987-95 [15291359.001]

[Cites] Arch Toxicol. 2005 Jan;79(1):54-61 [15368090.001]

[Cites] Oncogene. 2004 Oct 21;23(49):8049-64 [15377997.001]

[Cites] Toxicol Sci. 2004 Dec;82(2):419-28 [15470234.001]

[Cites] Arch Toxicol. 2005 Apr;79(4):183-91 [15526190.001]

[Cites] Toxicol Appl Pharmacol. 2004 Dec 1;201(2):156-65 [15541755.001]

[Cites] Curr Opin Hematol. 2005 Jan;12(1):1-6 [15604884.001]

[Cites] Anticancer Drugs. 2005 Feb;16(2):119-27 [15655408.001]

[Cites] J Biol Chem. 2005 May 20;280(20):19607-12 [15757911.001]

[Cites] Toxicol Sci. 2005 Jun;85(2):859-69 [15788719.001]

[Cites] Toxicol Sci. 2005 Jun;85(2):847-58 [15788720.001]

[Cites] J Clin Oncol. 2005 Apr 1;23(10):2396-410 [15800332.001]

[Cites] Biochemistry (Mosc). 2005 Feb;70(2):200-14 [15807660.001]

[Cites] Curr Med Res Opin. 2005 Mar;21(3):403-11 [15811209.001]

[Cites] Cancer Biol Ther. 2005 Apr;4(4):459-67 [15846091.001]

[Cites] Toxicology. 2005 Jul 1;211(1-2):115-23 [15863254.001]

[Cites] Toxicol Appl Pharmacol. 2005 Aug 1;206(1):54-65 [15963344.001]

[Cites] Environ Sci Technol. 2005 Aug 15;39(16):5933-9 [16173549.001]

[Cites] J Natl Cancer Inst. 2005 Oct 19;97(20):1539-47 [16234568.001]

[Cites] Toxicol Sci. 2006 Mar;90(1):49-60 [16322075.001]

[Cites] Free Radic Biol Med. 2006 Jan 1;40(1):138-45 [16337887.001]

[Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]

[Cites] Chem Biol Interact. 2006 Mar 10;160(1):1-40 [16430879.001]

[Cites] Toxicol Sci. 2006 May;91(1):70-81 [16436460.001]

[Cites] Environ Health Perspect. 2006 Mar;114(3):394-403 [16507463.001]

[Cites] Arch Biochem Biophys. 2006 Jul 1;451(1):68-78 [16579955.001]

[Cites] Toxicol Appl Pharmacol. 2006 Sep 1;215(2):208-17 [16580038.001]

[Cites] Crit Rev Toxicol. 2006 Feb;36(2):99-133 [16736939.001]

[Cites] Toxicol Appl Pharmacol. 2006 Oct 1;216(1):69-79 [16806342.001]

[Cites] Physiology (Bethesda). 2006 Aug;21:242-9 [16868313.001]

[Cites] Toxicol Appl Pharmacol. 2006 Nov 1;216(3):446-57 [16930657.001]

[Cites] Toxicol Appl Pharmacol. 2006 Nov 15;217(1):7-14 [16930658.001]

[Cites] Blood. 2007 Jan 15;109(2):740-6 [16968895.001]

[Cites] Br J Pharmacol. 2006 Dec;149(7):888-97 [17043674.001]

[Cites] Semin Cancer Biol. 2006 Dec;16(6):420-6 [17092741.001]

[Cites] Toxicol Sci. 2007 Feb;95(2):321-30 [17093206.001]

[Cites] Environ Health Perspect. 2006 Nov;114(11):1790-6 [17107869.001]

[Cites] Biochemistry. 2006 Dec 5;45(48):14552-8 [17128994.001]

[Cites] Mutat Res. 2007 Feb 3;615(1-2):75-86 [17134727.001]

[Cites] Rapid Commun Mass Spectrom. 2007;21(2):153-63 [17154358.001]

[Cites] Am J Physiol Heart Circ Physiol. 2007 Mar;292(3):H1227-36 [17172268.001]

[Cites] Exp Biol Med (Maywood). 2007 Jan;232(1):3-13 [17202581.001]

[Cites] Curr Top Microbiol Immunol. 2007;313:85-100 [17217040.001]

[Cites] Science. 2007 Jan 19;315(5810):387-9 [17234949.001]

[Cites] Toxicol Sci. 2007 May;97(1):103-10 [17324950.001]

[Cites] Biochemistry. 1992 Feb 18;31(6):1701-11 [1737025.001]

[Cites] Exp Toxicol Pathol. 2007 Aug;58(6):447-53 [17467962.001]

[Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):906-7 [17565151.001]

[Cites] Recent Pat Anticancer Drug Discov. 2006 Nov;1(3):327-46 [18221044.001]

[Cites] Arch Biochem Biophys. 1990 Feb 15;277(1):26-34 [2306121.001]

[Cites] Arch Biochem Biophys. 1989 Nov 1;274(2):375-93 [2802617.001]

[Cites] J Biol Chem. 1985 Oct 15;260(23):12554-60 [2864340.001]

[Cites] Biochemistry. 1979 Jun 12;18(12):2471-80 [375973.001]

[Cites] Arch Biochem Biophys. 1985 Oct;242(1):1-10 [3840344.001]

[Cites] Biochim Biophys Acta. 1979 Sep 28;574(3):487-94 [39620.001]

[Cites] Biochemistry. 1973 Sep 11;12(19):3616-21 [4788305.001]

[Cites] J Biol Chem. 1981 Nov 10;256(21):11112-6 [6116711.001]

[Cites] Biochemistry. 1984 Mar 13;23(6):1269-74 [6370306.001]

[Cites] Chem Biol Interact. 1983 Oct 15;47(1):29-44 [6640784.001]

[Cites] J Biol Chem. 1983 May 25;258(10):6266-71 [6853484.001]

[Cites] Methods Enzymol. 1982;89 Pt D:310-6 [7144576.001]

[Cites] Biochem Biophys Res Commun. 1993 May 14;192(3):1093-9 [8099479.001]

[Cites] J Biol Chem. 1996 Apr 19;271(16):9291-7 [8621591.001]

[Cites] J Biol Chem. 1996 Mar 22;271(12):6746-51 [8636095.001]

[Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3978-83 [9108090.001]

[Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]

[Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):124-33 [9450572.001]

[Cites] J Biochem Mol Toxicol. 1998;12(4):227-33 [9580875.001]

[Cites] Blood. 1998 Sep 1;92(5):1497-504 [9716575.001]

[Cites] Blood. 1998 Dec 1;92(11):4308-16 [9834237.001]

[Cites] J Bioenerg Biomembr. 1998 Oct;30(5):499-510 [9932652.001]

[Cites] Eur J Biochem. 1999 Jun;262(2):386-95 [10336623.001]

[Cites] Exp Cell Res. 1999 Jun 15;249(2):413-21 [10366441.001]

[Cites] Am J Physiol. 1999 Nov;277(5 Pt 2):F685-96 [10564231.001]

[Cites] Biochim Biophys Acta. 2000 Jan 10;1456(2-3):67-76 [10627296.001]

[Cites] Oncogene. 2000 Jan 13;19(2):307-14 [10645010.001]

[Cites] Toxicol Appl Pharmacol. 2000 Mar 1;163(2):203-7 [10698679.001]

[Cites] Oncologist. 2001;6 Suppl 2:1-2 [11331433.001]

[Cites] Chem Res Toxicol. 2001 Jun;14(6):651-6 [11409934.001]

[Cites] Toxicology. 2001 Oct 5;167(1):73-81 [11557131.001]

[Cites] Toxicol Appl Pharmacol. 2001 Oct 15;176(2):127-44 [11601889.001]

[Cites] J Cell Biol. 2001 Dec 10;155(6):1003-15 [11739410.001]

[Cites] J Biol Chem. 2002 Feb 22;277(8):6097-103 [11744738.001]

[Cites] Oncogene. 2001 Nov 15;20(52):7579-87 [11753636.001]

[Cites] Blood. 2002 May 1;99(9):3136-43 [11964275.001]

[Cites] Toxicol Lett. 2002 Jul 7;133(1):1-16 [12076506.001]

[Cites] Cancer Res. 2002 Jul 15;62(14):3893-903 [12124315.001]

[Cites] Biochem J. 2002 Oct 15;367(Pt 2):541-8 [12149099.001]

[Cites] Toxicol Appl Pharmacol. 2002 Aug 1;182(3):208-18 [12183100.001]

[Cites] Arch Biochem Biophys. 2002 Oct 15;406(2):271-4 [12361715.001]

[Cites] Toxicol Sci. 2002 Nov;70(1):13-9 [12388830.001]

[Cites] Biochem J. 2003 Apr 15;371(Pt 2):495-503 [12519079.001]

[Cites] Chem Res Toxicol. 2003 Mar;16(3):409-14 [12641442.001]

[Cites] J Environ Qual. 2003 Mar-Apr;32(2):535-40 [12708677.001]

[Cites] J Biol Chem. 2003 Jul 18;278(29):26757-64 [12740376.001]

[Cites] Mol Pharmacol. 2003 Jun;63(6):1349-55 [12761345.001]

[Cites] Cancer Cell. 2003 May;3(5):497-509 [12781367.001]

(PMID = 18431449.001).

[ISSN] 0793-0291

[Journal-full-title] Metal-based drugs

[ISO-abbreviation] Met Based Drugs

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC2292810

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience.

Using current treatment regimens, over 90% of patients with acute promyelocytic leukemia will achieve complete remission (CR).

[MeSH-major] Hematologic Diseases / complications. Hematologic Diseases / drug therapy. Leukemia, Promyelocytic, Acute / complications. Leukemia, Promyelocytic, Acute / drug therapy

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Blood Disorders.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Leukemia. 2000 Mar;14(3):393-8 [10720132.001]

[Cites] Blood. 2008 Mar 1;111(5):2505-15 [18299451.001]

[Cites] Leukemia. 2002 Jun;16(6):1127-30 [12040443.001]

[Cites] Eur J Haematol. 2002 May;68(5):310-3 [12144538.001]

[Cites] Ann Pharmacother. 2002 Dec;36(12):1900-6 [12452754.001]

[Cites] Br J Haematol. 2003 Jan;120(2):266-70 [12542484.001]

[Cites] Leukemia. 2003 Aug;17(8):1454-63 [12886231.001]

[Cites] Bone Marrow Transplant. 2003 Oct;32(8):843-6 [14520432.001]

[Cites] Leukemia. 2004 Apr;18(4):879-80 [14961031.001]

[Cites] Leuk Res. 2004 Sep;28(9):991-4 [15234578.001]

[Cites] Cancer. 1996 Dec 15;78(12):2510-4 [8952559.001]

[Cites] Blood. 1998 Aug 1;92(3):784-9 [9680345.001]

[Cites] Leuk Lymphoma. 1999 Apr;33(3-4):219-29 [10221502.001]

[Cites] Crit Rev Oncol Hematol. 2005 Nov;56(2):261-74 [16236522.001]

[Cites] Leukemia. 2006 Jan;20(1):35-41 [16307026.001]

[Cites] Int J Hematol. 2006 May;83(4):337-40 [16757435.001]

[Cites] Ann Oncol. 2007 Jan;18(1):7-12 [16790518.001]

[Cites] Best Pract Res Clin Haematol. 2007 Mar;20(1):57-65 [17336255.001]

[Cites] Pediatr Blood Cancer. 2007 May;48(5):582-5 [16123994.001]

[Cites] Cancer. 2007 Apr 1;109(7):1355-9 [17326049.001]

[Cites] Leuk Res. 2007 May;31(5):703-5 [16876245.001]

[Cites] Biol Blood Marrow Transplant. 2007 Sep;13(9):997-1004 [17697961.001]

[Cites] Leuk Res. 2007 Nov;31(11):1585-7 [17416415.001]

[Cites] Haematologica. 2007 Dec;92(12):1615-22 [18055984.001]

[Cites] Pediatr Blood Cancer. 2008 Mar;50(3):657-60 [17437290.001]

[Cites] Blood. 2008 Feb 1;111(3):1078-84 [17975017.001]

[Cites] Ann Transplant. 2007;12(3):33-8 [18290568.001]

[Cites] J Clin Oncol. 2001 Oct 15;19(20):4023-8 [11600603.001]

(PMID = 19340529.001).

[ISSN] 1865-3774

[Journal-full-title] International journal of hematology

[ISO-abbreviation] Int. J. Hematol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P30 CA016672

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ NIHMS633724; NLM/ PMC4199302

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Significance of persistent Auer rods and cytogenetic abnormality after first cycle of therapy for acute promyelocytic leukaemia.

[MeSH-major] Bone Marrow Examination. Chromosome Aberrations. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / pathology

[MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 17. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Humans. In Situ Hybridization, Fluorescence. Male. Oncogene Proteins, Fusion / genetics. Remission Induction. Translocation, Genetic. Tretinoin / therapeutic use

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. DAUNORUBICIN .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Br J Haematol. 2008 Sep;142(6):998-1000 [18544082.001]

(PMID = 17374141.001).

[ISSN] 0007-1048

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; ZS7284E0ZP / Daunorubicin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Spontaneous regression of aleukemic leukemia cutis harboring a NPM/RARA fusion gene in an infant with cutaneous mastocytosis.

Aleukemic leukemia cutis has been rarely reported in infant leukemia.

This report describes a 6-month-old boy with aleukemic leukemia cutis, which regressed without any treatments within 6 months.

Interestingly, a cytogenetic analysis disclosed a leukemia clone with the karyotype of 46, XY, t(5;17)(q35;q12), which generated nucleophosmin (NPM)-retinoic acid receptor alpha fusion (RARA) fusion transcripts.

The patient simultaneously had cutaneous mastocytosis, which also disappeared with the leukemia cutis.

The present case is partially compatible with systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disorder, proposed by the WHO classification, and it is also suggestive of the initiation or early stage of acute promyelocytic leukemia.

[MeSH-major] Leukemia / complications. Mastocytosis, Cutaneous / complications. Oncogene Proteins, Fusion / genetics. Remission, Spontaneous

[MeSH-minor] Humans. Infant. Leukemia, Promyelocytic, Acute. Male

Genetic Alliance. consumer health - Mast cell disease.

Genetic Alliance. consumer health - Cutaneous mastocytosis.

MedlinePlus Health Information. consumer health - Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 1996 Feb 1;87(3):882-6 [8562957.001]

[Cites] Br J Haematol. 2002 Jun;117(3):513-24 [12028017.001]

[Cites] Pediatr Dermatol. 2005 Jan-Feb;22(1):26-30 [15660893.001]

[Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]

[Cites] Blood. 1993 Jul 15;82(2):544-6 [8329709.001]

[Cites] Nat Genet. 1997 Sep;17 (1):109-13 [9288109.001]

[Cites] Science. 1990 Sep 28;249(4976):1577-80 [2218500.001]

[Cites] EMBO J. 1993 Mar;12(3):1161-7 [8384553.001]

[Cites] Hum Mol Genet. 1999 Sep;8(9):1741-9 [10441338.001]

[Cites] J Pediatr. 1997 Aug;131(2):300-3 [9290620.001]

[Cites] Pediatr Dermatol. 2004 Jul-Aug;21(4):458-61 [15283790.001]

[Cites] Leukemia. 2001 Sep;15(9):1359-68 [11516096.001]

[Cites] J Pediatr Hematol Oncol. 2000 May-Jun;22(3):252-5 [10864057.001]

[Cites] Oncogene. 2001 Oct 29;20(49):7186-203 [11704847.001]

[Cites] J Am Acad Dermatol. 1994 Jun;30(6):1041-3 [8188876.001]

[Cites] Int Arch Allergy Immunol. 2002 Feb;127(2):140-2 [11919425.001]

[Cites] Arch Dermatol. 1993 Oct;129(10):1301-6 [8215495.001]

[Cites] Leukemia. 2002 Oct;16(10):1959-73 [12357347.001]

[Cites] Nature. 1990 Oct 11;347(6293):558-61 [2170850.001]

[Cites] Int J Hematol. 2007 Oct;86(3):246-9 [17988991.001]

[Cites] Blood. 2000 Aug 15;96(4):1297-308 [10942371.001]

[Cites] Oncogene. 1996 Jan 18;12(2):265-75 [8570204.001]

[Cites] Leukemia. 1988 Oct;2(10):672-6 [3172843.001]

[Cites] Oncogene. 1999 Jan 21;18(3):633-41 [9989813.001]

(PMID = 19052694.001).

[ISSN] 1865-3774

[Journal-full-title] International journal of hematology

[ISO-abbreviation] Int. J. Hematol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / NPM-RARalpha protein, human; 0 / Oncogene Proteins, Fusion

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.

A previous report of the Programa de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA) Group showed that a risk-adapted strategy combining all-trans retinoic acid (ATRA) and anthracycline monochemotherapy for induction and consolidation in newly diagnosed acute promyelocytic leukemia results in an improved outcome.

Patients achieving complete remission received 3 courses of consolidation followed by maintenance with ATRA and low-dose chemotherapy.

[MeSH-major] Anthracyclines / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18664623.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin